Below are the most recent publications written about "Histamine Antagonists" by people in Profiles.
-
Chu AWL, Wen A, Guyatt GH, Rao M, Bakaa L, Zhao IX, Roldan Y, Spergel JM, LeBovidge J, Boguniewicz M, Martin SA, Lind ML, Silverberg JI, Lio PA, Asiniwasis RN, Wang J, De Benedetto A, Greenhawt M, Wheeler KE, Ong PY, Frazier WT, Nelson H, O'Brien M, Capozza K, Begolka WS, Gardner DD, Schneider LC, Chu DK. Antihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials. BMJ. 2026 Jul 29; 394:e100163.
-
Kim JY, Shin DW, Kim Z, Kim SH, Son KL, Kim SH, Yoon HJ. Neuropsychiatric adverse effects of antihistamine: A nationwide data-based epidemiological study in South Korea. Asian Pac J Allergy Immunol. 2026 Jun; 44(2):392-398.
-
Tocci EM, Robinson A, Belazarian L, Foley E, Wiss K, Silvestri DL. Excipients in Oral Antihistamines Can Perpetuate Allergic Contact Dermatitis. Pediatr Dermatol. 2015 Nov-Dec; 32(6):e242-4.
-
Alvarez CA, Mortensen EM, Makris UE, Berlowitz DR, Copeland LA, Good CB, Amuan ME, Pugh MJ. Association of skeletal muscle relaxers and antihistamines on mortality, hospitalizations, and emergency department visits in elderly patients: a nationwide retrospective cohort study. BMC Geriatr. 2015 Jan 27; 15:2.
-
McEnery-Stonelake M, Silvestri DL. Contact allergens in oral antihistamines. Dermatitis. 2014 Mar-Apr; 25(2):83-8.
-
Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med. 2013 Apr 25; 368(17):1625-34.
-
Milliken D, Roosinovich E, Wilton H, Lipworth AD, Moore D, Morris-Jones S, Marks DJ. Drug fever and DRESS syndrome. Br J Hosp Med (Lond). 2011 Apr; 72(4):224-8.
-
Ligneau X, Landais L, Perrin D, Piriou J, Uguen M, Denis E, Robert P, Parmentier R, Anaclet C, Lin JS, Burban A, Arrang JM, Schwartz JC. Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol. 2007 Apr 15; 73(8):1215-24.
-
Parmentier R, Anaclet C, Guhennec C, Brousseau E, Bricout D, Giboulot T, Bozyczko-Coyne D, Spiegel K, Ohtsu H, Williams M, Lin JS. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol. 2007 Apr 15; 73(8):1157-71.
-
Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J Pharmacol Exp Ther. 2007 Jan; 320(1):365-75.